Reproductive Medicine Associates of New Jersey
Trial Pipeline
The EPIC Study: Exploring Paternal Age and the Influence on Blastocyst Culture
NCT06629766
Male Infertility and Assisted Reproductive Technologies Research Biobank
NCT06880302
Quantifying Uterine Elastography in Menstruating Women
NCT06816381
Validating Incubators in the Lab: Optimizing Culture and Investigating blasTulation Yield
NCT06214936
Platelet Rich Plasma for Insufficient Endometrium
NCT05538338
Discarded Materials Study
NCT01219335
Oocyte Survival After Vitrification With Slush Nitrogen Compared With Liquid Nitrogen
NCT04342364
Embryo DNA Repair Capacity Project
NCT03953859
Evaluation of the Impact of Reduced Oxygen Concentration on Embryonic Development
NCT02919384
Effects of Varied Estrogen Doses on Endometrial Receptivity
NCT02458404
Next Generation Sequencing Screening for Embryonic Ploidy Status
NCT02032264
Evaluation of Discarded Laboratory Pathological Specimens and Media
NCT01219439
Retrospective Database Studies
NCT01219296
What the Pipeline for Reproductive Medicine Associates of New Jersey Shows
According to the ClinicalTrials.gov registry, Reproductive Medicine Associates of New Jersey is linked to 13 US clinical trials across every stage of research activity. Of those, 6 studies are currently recruiting — about 46% of the sponsor's indexed portfolio — and 7 are already marked complete, representing roughly 54% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Reproductive Medicine Associates of New Jersey reports 0 late-stage studies (Phase 3 and Phase 4 combined) and 0 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Reproductive Medicine Associates of New Jersey is Infertility with 6 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.